Article info
PDFTherapeutics
Systematic review and meta-analysis
Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma
- Correspondence to: Professor Neil C Thomson, Institute of Infection, Immunity & Inflammation, University of Glasgow and Respiratory Medicine, Gartnavel General Hospital, Glasgow, G12 OYN, UK; neil.thomson{at}glasgow.ac.uk
Citation
Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma
Publication history
- First published March 13, 2014.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions